Department of Otolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, ASST Lariana, Ospedale Sant'Anna, University of Insubria, 22042, Como, San Fermo Della Battaglia, Italy.
Head and Neck Surgery and Forensic Dissection Research Center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, 21100, Varese, Italy.
Eur Arch Otorhinolaryngol. 2024 Jul;281(7):3601-3613. doi: 10.1007/s00405-024-08500-8. Epub 2024 Mar 14.
To analyze oncological outcomes of endoscopic surgical treatment of locally recurrent EBV-related undifferentiated non-keratinizing nasopharyngeal carcinoma (uNK-NPC) in a non-endemic area.
Retrospective review of patients affected by recurrent uNK-NPC treated with nasopharyngeal endoscopic resection (NER) in a tertiary-care referral center from 2003 to 2022, by evaluating survival rates, prognostic factors, and follow-up strategies.
The oncological outcomes of 41 patients were analyzed, over a mean follow-up period of 57 months. The 5-year overall, disease-specific, and disease-free survival of the cohort were 60.7% ± 8.9%, 69% ± 9%, and 39.7% ± 9.2%, respectively. The local (rT) and regional (rN) extension of recurrent disease, stage of disease, and status of resection margins appeared to significantly influence survivals. After a mean follow-up period of 21 months, a further recurrence after NER was observed in 36.6% of cases. Skull base osteonecrosis induced by previous irradiation and post-surgical bone remodeling represent the major challenges for early detection of further local relapses during postoperative follow-up.
NER appeared as a safe and effective treatment for recurrent uNK-NPC. The adequate selection of patients eligible for NER is essential, to maximize the chances to cure and minimize the risk of local complications.
分析非流行地区内镜手术治疗局部复发性 EBV 相关未分化非角化性鼻咽癌(uNK-NPC)的肿瘤学结果。
回顾性分析 2003 年至 2022 年在一家三级转诊中心接受鼻咽内镜切除术(NER)治疗的复发性 uNK-NPC 患者的生存情况,评估生存率、预后因素和随访策略。
对 41 例患者的肿瘤学结果进行了分析,平均随访时间为 57 个月。该队列的 5 年总生存率、疾病特异性生存率和无病生存率分别为 60.7%±8.9%、69%±9%和 39.7%±9.2%。复发性疾病的局部(rT)和区域(rN)扩展、疾病分期和切除边缘状态似乎显著影响生存率。在 NER 后平均 21 个月的随访期间,36.6%的病例出现了进一步的复发。先前放疗引起的颅底骨坏死和术后骨重塑是术后随访中早期发现进一步局部复发的主要挑战。
NER 似乎是治疗复发性 uNK-NPC 的一种安全有效的方法。适当选择适合 NER 的患者至关重要,以最大限度地提高治愈机会并降低局部并发症的风险。